GAITHERSBURG, Md., Nov. 14,
2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:
YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, is pleased to announce that
Noble Capital Markets ("Noble") has initiated equity research
coverage on the Company with an "Outperform" rating and a 12-month
price target of US$5.25 per share.
The full report by Noble Capital Markets Senior Healthcare Services
& Medical Device Analyst Gregory
Aurand, as well as news and advanced market data on YS
Biopharma, is available on Channelchek. The report can also be
accessed through the Company's investor relations website here.
Highlights from the report include:
- PIKA Immunomodulating Platform. The novel PIKA
technology has the capability to target and accelerate the immune
response in a wide variety of vaccines and immuno-oncology
therapeutics. PIKA activates and enhances the body's immune
response, increasing the effectiveness of vaccines. In
immuno-oncology, with its multiple modes of action able to induce
the production of multiple tumor-inhibitory cytokines and tumor
cell apoptosis, PIKA could be applied to broad-spectrum anti-tumor
activity in cancers.
- Significant Opportunities in Anti-Viral
and Immuno-Oncology Markets. There are large unmet needs
in Africa, Southeast Asia and China, among other parts of the world, in
rabies, hepatitis B and cancers. The Asia-Pacific region is expected to have the
highest growth rate in the world with higher levels of utilization
of immunotherapies, driven by low vaccine penetration, increasing
cancer prevalence, and improving patient awareness and disposable
income.
- Commercialized Rabies Vaccine. Currently, YS
Biopharma markets the YSJA rabies virus vaccine, the first
aluminum-free lyophilized rabies vaccine launched in China. The YSJA vaccine, a more traditional
vaccine, is more effective and has a better safety profile than
other vaccines and has achieved approximately 11% market share
since launch in 2020, although the pandemic in calendar 2023 has
had a negative effect on the supply chain and production output.
The YSJA vaccine not only helps support the buildout of the
commercial infrastructure but also provides support for the PIKA
research and development pipeline.
- Initiating With Outperform. Noble's $5.25 1-year price target is based on FY2029 EPS
of RMB6.93 ($0.95), discounted at 30% and applying a Nasdaq
earnings multiple of 20x. The multiple reflects an average trailing
Nasdaq P/E ratio that Noble believes reflects the growth
opportunity. For a smaller company with less certain cash flows,
and development and product risk, Noble assigns a higher discount
rate.
All reports on YS Biopharma prepared by analysts represent the
views of such analysts and are not necessarily those of the
Company. YS Biopharma is not responsible for the content, accuracy,
or timelines provided by analysts. YS Biopharma does not expressly
or by implication warrant or assume any legal liability or
responsibility for the accuracy, completeness, or usefulness of any
information, assumption, data, forecast, price target, estimate, or
projection contained in the reports or industry notes provided by
analysts, and the dissemination of such reports or industry notes
does not necessarily constitute or imply YS Biopharma's endorsement
or recommendation. The Company is a participant in the Company
Sponsored Research Program ("CSRP") at Noble Capital Markets and
Noble Capital Markets receives compensation from the Company for
such participation. No part of the CSRP compensation was, is, or
will be directly or indirectly related to any specific
recommendations or views expressed by the analyst in this research
report.
About YS Biopharma
YS Biopharma is a global
biopharmaceutical company dedicated to discovering, developing,
manufacturing, and delivering new generations of vaccines and
therapeutic biologics for infectious diseases and cancer. It has
developed a proprietary PIKA® immunomodulating
technology platform and a new generation of preventive and
therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B,
Influenza, Shingles, and other virus infections.
YS Biopharma operates in China, the United
States, Singapore, and the Philippines, and is led by a management team
that combines rich local expertise and global experience in the
biopharmaceutical industry. For more information, please
visit investor.ysbiopharm.com.
About Noble Capital Markets
Noble Capital Markets,
Inc. was incorporated in 1984 as a full-service SEC / FINRA
registered broker-dealer, dedicated exclusively to serving
underfollowed small / microcap companies through investment
banking, wealth management, trading & execution, and equity
research activities. Over the past 37 years, Noble has raised
billions of dollars for these companies and published more than
45,000 equity research reports. For more information, please visit
www.noblecapitalmarkets.com, or email
contact@noblecapitalmarkets.com.
About Channelchek
Channelchek (.com) is a
comprehensive investor-centric portal - featuring more than 6,000
emerging growth companies - that provides advanced market data,
independent research, balanced news, video webcasts, exclusive
c-suite interviews, and access to virtual road shows. The site is
available to the public at every level without cost or obligation.
Research on Channelchek is provided by Noble Capital Markets, Inc.,
an SEC / FINRA registered broker-dealer since 1984. For more
information, please visit www.channelchek.com, or email
contact@channelchek.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements'' within the meaning of Section 27A of the Securities
Act of 1933, as amended, Section 21E of the Securities Exchange Act
of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995. All statements other than statements of historical or
current fact included in this press release are forward-looking
statements, including but not limited to statements regarding the
expected growth of YS Biopharma, the development progress of all
product candidates, the progress and results of all clinical
trials, YS Biopharma's ability to source and retain talent, and the
cash position of YS Biopharma following the closing of the Business
Combination. Forward-looking statements may be identified by the
use of words such as "estimate," "plan," "project," "forecast,"
"intend," "will," "expect," "anticipate," "believe," "seek,"
"target" or other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. These statements are based on various assumptions, whether
identified in this press release, and on the current expectations
of YS Biopharma's management and are not predictions of actual
performance.
These statements involve risks, uncertainties and other factors
that may cause actual results, levels of activity, performance, or
achievements to be materially different from those expressed or
implied by these forward-looking statements. Although YS Biopharma
believes that it has a reasonable basis for each forward-looking
statement contained in this press release, YS Biopharma cautions
you that these statements are based on a combination of facts and
factors currently known and projections of the future, which are
inherently uncertain. In addition, there are risks and
uncertainties described in the final prospectus relating to the
proposed Business Combination, and other documents filed by YS
Biopharma from time to time with the SEC. These filings may
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements.
YS Biopharma cannot assure you that the forward-looking
statements in this press release will prove to be accurate. These
forward-looking statements are subject to a number of risks and
uncertainties, including, among others, the ability to recognize
the anticipated benefits of the Business Combination, costs related
to the transaction, the impact of the global COVID-19 pandemic, the
risk that the transaction disrupts current plans and operations as
a result of the consummation of the transaction, the outcome of any
potential litigation, government or regulatory proceedings, the
sales performance of the marketed vaccine product and the clinical
trial development results of the product candidates of YS
Biopharma, and other risks and uncertainties, including those
included in YS Biopharma's filings with the SEC. There may be
additional risks that YS Biopharma does not presently know or that
YS Biopharma currently believes are immaterial that could also
cause actual results to differ from those contained in the
forward-looking statements. In light of the significant
uncertainties in these forward-looking statements, nothing in this
press release should be regarded as a representation by any person
that the forward-looking statements set forth herein will be
achieved or that any of the contemplated results of such
forward-looking statements will be achieved. The forward-looking
statements in this press release represent the views of YS
Biopharma as of the date of this press release. Subsequent events
and developments may cause those views to change. However, while YS
Biopharma may update these forward-looking statements in the
future, there is no current intention to do so, except to the
extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing the views of YS
Biopharma as of any date subsequent to the date of this press
release. Except as may be required by law, YS Biopharma does not
undertake any duty to update these forward-looking statements.
Investor Relations Contacts
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/noble-capital-markets-initiates-coverage-on-ys-biopharma-with-outperform-rating-and-us5-25-price-target-301987487.html
SOURCE YS Biopharma Co., Ltd.
